Deals wrap: Key facts about the Sanofi/Genzyme deal
French drugmaker Sanofi-Aventis agreed to buy Genzyme with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs, the companies said. Reuters has a factbox about the two companies, a timeline of Sanofi’s quest for Genzyme and a look at Sanofi’s patient CEO.
The London Stock Exchange’s bid to take over Canada’s TMX Group is likely to navigate through a battery of regulatory reviews and emerge intact, even though investors are nervous about its chances.
In Asia however, tough regulatory regimes, cumbersome ownership structures and protectionist-minded governments mean cross-border mergers involving regional markets will be difficult.
Jeff Carter at Points and Figures looks for the synergies in the Deutsche Boerse/NYSE deal.
China’s new review body for inward M&A could bring some much-needed transparency to the deal approval process and even make it quicker for foreign companies to get tie-ups with mainland firms past the authorities.